Silencing the Virus at the RNA Level: How HBV-Targeted Antisense Oligonucleotide (ASO) Therapeutics Are Redefining Chronic Hepatitis B Treatment
A data-grounded look at who is innovating, where intellectual-property activity is concentrated, and what it means for functional-cure strategies, commercialization, and IP strategy.
Report details
HBV-Targeted Antisense Oligonucleotide (ASO) Therapeutics — Patent Landscape Study Report
A next-generation treatment approach for chronic hepatitis B
This report explores the emergence of HBV-Targeted Antisense Oligonucleotide (ASO) Therapeutics as a next-generation treatment approach for chronic hepatitis B (CHB), enabling sequence-specific targeting of HBV RNA to suppress viral gene expression and reduce viral antigen production. It examines the technological foundations, therapeutic applications, and evolving patent landscape, providing insight into who is innovating, where intellectual-property activity is concentrated, and what these trends mean for functional-cure strategies, commercialization, and IP strategy.
The report covers key technologies including HBV-specific ASO sequences, viral RNA targeting, HBsAg suppression, RNA degradation and gene-expression inhibition, chemically modified oligonucleotides, backbone and sugar modifications, nuclease resistance, hepatocyte-targeted delivery, intracellular uptake, pharmacokinetic optimization, dosing strategies, biomarker-guided treatment, and combination therapies. It also analyzes leading assignees, patent-filing trends, jurisdictions, technology evolution, therapeutic applications, competitive dynamics, whitespace opportunities, and the future outlook for precision oligonucleotide-based HBV treatment.
Built for everyone shaping the future of HBV treatment
Each audience gets a clear view of the landscape and what to do with it.
When suppressing the virus is not the same as curing the disease
Chronic hepatitis B remains a major global health burden despite the availability of an effective vaccine. Current standard therapies, namely nucleos(t)ide analogues and pegylated interferon, can suppress viral replication, but they rarely clear the hepatitis B surface antigen (HBsAg), often require long-term or lifelong treatment, and leave the persistent viral reservoir largely untouched; interferon is also limited by tolerability. High circulating HBsAg is thought to contribute to immune dysfunction, which is why reducing it is a central goal of functional-cure strategies. HBV-targeted antisense oligonucleotides are short, chemically modified nucleic acids designed to bind specific HBV RNA sequences and trigger their degradation or block their expression, lowering viral antigen production directly at its source. The approach is promising but not without limits: efficient and selective delivery to hepatocytes, durability of response after treatment, sequence coverage across HBV genotypes and integrated viral DNA, safety and tolerability of oligonucleotide chemistries, and the need for combination regimens that restore immune control all remain open questions.
Table of contents
Twelve chapters, from HBV-targeted ASO fundamentals to patent landscape intelligence. Click any chapter to expand.
Core capabilities of HBV-targeted ASO therapeutics
The properties that make antisense oligonucleotides a precise tool against hepatitis B.
Why conventional HBV therapy falls short, and what stays hard
What HBV-targeted ASO therapeutics aim to address, and where the limits are.
Where HBV-targeted ASO therapeutics create value
Therapeutic uses where precise, RNA-level control of the virus is a competitive edge.
Who is innovating, where, and in which areas
The study covers methodology and scope, strategic insights, the assignee picture, filing activity over time, jurisdiction coverage, technology segmentation across HBV-targeting sequences, oligonucleotide chemistry and modifications, hepatocyte-targeted delivery, dosing and biomarker strategies, and combination therapies, and the whitespace and strategic opportunities for new filings and licensing.
Request Your Sample Report Now!
